MS and Demyelinating Disorders

As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

A case report reveals cognitive decline and brain atrophy in a patient with NMOSD, highlighting potential subclinical neurodegeneration despite limited relapses.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

The assistant professor of neurology at Northwestern University explained key diagnostic, therapeutic, and management considerations for clinicians caring for patients with NMOSD across diverse and evolving clinical scenarios.

Findings from a second phase 3 trial, dubbed FENhance 1, assessing fenebrutinib in patients with relapsing multiple sclerosis are anticipated by the first half of 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

Obexelimab shows promising results in reducing lesions in relapsing multiple sclerosis, highlighting its potential as a new treatment for autoimmune diseases.

Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure during pregnancy and lactation in women with MS.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.